TNF was originally described as a circulating factor that can cause necrosis of tumours, but
has since been identified as a key regulator of the inflammatory response. This review …

During the past 30 years, elucidation of the pathogenesis of rheumatoid arthritis, Crohn's
disease, psoriasis, psoriatic arthritis and ankylosing spondylitis at the cellular and molecular …

Background Neurosarcoidosis is a rare variant of sarcoidosis and is only described in small
cohort studies. We define clinical features, treatment and outcome of patients with …

This is an update on sarcoidosis, focusing on etiology, diagnosis, and treatment. In the area
of etiopathogenesis, we now have a better understanding of the immune response that …

Sarcoidosis is a systemic disease of unknown etiology defined by the presence of
noncaseating granulomatous inflammation that can cause organ damage and diminished …

Sarcoidosis is a multisystem granulomatous disease with nonspecific clinical manifestations
that commonly affects the pulmonary system and other organs including the eyes, skin, liver …

Increased levels of tumor necrosis factor (TNF) α have been linked to a number of
pulmonary inflammatory diseases including asthma, chronic obstructive pulmonary disease …

Objective Tuberculosis (TB) is associated with anti–tumor necrosis factor (anti‐TNF)
monoclonal antibody (mAb) therapy, but whether this association is drug‐specific remains a …

Pulmonary sarcoidosis presents substantial management challenges, with limited evidence
on effective therapies and phenotypes. In the absence of definitive evidence, expert …

Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …